Pasar al contenido principal

ESTUDIO “MIRROR”: CARACTERIZACION DEL MICROAMBIENTE TUMORAL INMUNOLOGICO EN CANCER DE PULMÓN SEGUN LA EXPOSICIÓN AL GAS RADÓN Y/O TABACO

PI21/01653

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2021
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)
Centro realización INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease

  • Seguí, Elia|||0000-0001-7770-9825
  • Torres Canizales, Juan|||0000-0002-7138-5732
  • Auclin, E.
  • Casadevall, David|||0000-0002-3986-2084
  • Peiro Carmona, Sara
  • Aguilar Company, Juan|||0000-0002-9838-1950
  • García de Herreros, Marta|||0000-0001-8010-3584
  • Gorría, Teresa
  • Laguna, Juan Carlos|||0000-0002-2357-1186
  • Rodríguez, Marta
  • González, Azucena
  • Epaillard, N.|||0000-0001-7543-491X
  • Gavira, Javier|||0000-0001-6385-3519
  • Bolaño, Victor
  • Tapia, Jose C.|||0000-0001-6545-8862
  • Tagliamento, M.
  • Teixidó, C.
  • Arasanz, Hugo|||0000-0001-6838-6702
  • Pilotto, S.|||0000-0003-2229-4874
  • Lopez Castro, Rafael|||0000-0003-4770-4710
  • Mielgo-Rubio, Xabier|||0000-0002-0985-6150
  • Urbano, C.
  • Recondo, G.
  • Diaz Pavon, Mar|||0009-0001-2378-5432
  • Bluthgen, M.V.
  • Minatta, J.N.|||0000-0002-3531-1920
  • Lupinacci, L.
  • Brasó-Maristany, F.
  • Prat, A.
  • Vlagea, Alexandru|||0000-0003-3169-4597
  • Mezquita, Laura|||0000-0003-0936-7338
Inflammation and neutrophils play a central role in both COVID-19 disease and cancer. We aimed to assess the impact of pre-existing tumor-related inflammation on COVID-19 outcomes in patients with cancer and to elucidate the role of circulating neutrophil subpopulations. We conducted a multicenter retrospective analysis of 524 patients with cancer and SARS-CoV-2 infection, assessing the relationship between clinical outcomes and circulating inflammatory biomarkers collected before and during COVID-19 infection. Additionally, a single-center prospective cohort study provided data for an exploratory analysis, assessing the immunophenotype of circulating neutrophils and inflammatory cytokines. The primary endpoints were 30-day mortality and the severity of COVID-19 disease. Prior to COVID-19, 25% of patients with cancer exhibited elevated dNLR, which increased to 55% at the time of COVID-19 diagnosis. We developed the FLARE score, incorporating both tumor- and infection-induced inflammation, which categorized patients into four prognostic groups. The poor prognostic group had a 30-day mortality rate of 68%, significantly higher than the 23% in the favorable group (p < 0.0001). This score proved to be an independent predictor of early mortality. This prospective analysis revealed a shift towards immature forms of neutrophils and higher IL-6 levels in patients with cancer and severe COVID-19 infection. A pre-existing tumor-induced pro-inflammatory state significantly impacts COVID-19 outcomes in patients with cancer. The FLARE score, derived from circulating inflammatory markers, emerges as an easy-to-use, globally accessible, effective tool for clinicians to identify patients with cancer at heightened risk of severe COVID-19 complications and early mortality who might benefit most from immediate and intensive treatment strategies. Furthermore, our findings underscore the significance of immature neutrophils in the progression of COVID-19 in patients with cancer, advocating for further investigation into how these cells contribute to both cancer and COVID-19 disease.